Sino Biopharmaceutical (HK:1177) has released an update.
Shareholders of Sino Biopharmaceutical overwhelmingly approved all resolutions at the Annual General Meeting on June 5, 2024, including the adoption of financial statements and director reports for 2023, the payment of a final dividend, the re-election of several directors, and mandates to issue and buy back shares. The resolutions received high approval rates, with the re-election of directors and the issuance and buyback of shares passing with substantial majority votes. The meeting had full director attendance, except for two absences due to business commitments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
